CorMedix Inc. (CRMD) is a New Jersey-based commercial-stage biopharmaceutical company that sells products into institutional care settings. Its flagship asset is DefenCath, an FDA-approved antimicrobial catheter lock solution for dialysis patients, and it has broadened its portfolio through the acquisition of Melinta's hospital-focused brands and a pending deal for Heron Therapeutics' commercial assets. In Monday's session, the stock traded at $4.81, a gain of 3.22% from the prior close of $4.66, confirming an upward move on the day. The immediate trigger identified by markets was a fresh insider purchase by the company's chief executive, disclosed in a regulatory filing before the opening bell.
Monday's filing showed that Joseph Todisco, CorMedix's chairman and CEO, acquired 80,000 common shares on November 13 in a series of open-market transactions priced between $4.85 and $5.00, for a total of approximately $391,200. The purchases came one trading session after the stock touched $4.65, its lowest level in more than a year.
The signal mattered more than the dollar amount. Over the prior twelve months, no insider purchases had been disclosed at CorMedix, while roughly $2.2 million of insider sales were recorded. A first buy from the top executive — executed in the open market rather than through an award or option exercise — is the sort of alignment cue that small-cap investors weight heavily, particularly when it arrives at a multi-month low. It is also modest relative to a market capitalization of roughly $380 million, which explains why the initial premarket premium of more than 8% did not hold.
The rebound unfolded against a steep recent drawdown. Third-quarter results released November 12 showed consolidated revenue of $54.5 million, ahead of the $51.2 million street consensus, but a GAAP net loss of $14.7 million, or $0.19 per share, and adjusted EBITDA that fell to $3.1 million. DefenCath net sales dropped to $17.2 million year over year as the product moved into the post-TDAPA reimbursement period at lower net pricing.
Management maintained full-year 2026 revenue guidance of $325 million to $345 million and narrowed adjusted EBITDA guidance to $130 million to $140 million, yet suspended previously issued 2027 DefenCath guidance pending clarity on pricing and Medicare Advantage contracting. That visibility gap, alongside dilution from the 14.58 million shares earmarked for the Heron transaction, drove the stock to a loss of roughly 25% on October 30 and further weakness into mid-November. Analyst actions have been measured rather than punitive: Oppenheimer trimmed its target to $13 from $15 while keeping an Outperform rating, and Needham moved its target to $14 with a Buy rating.
Volume was elevated. Roughly 2.0 million shares had changed hands by mid-afternoon, well above the 20-day average near 1.2 million, indicating the move drew genuine participation rather than a thin tape. The stock's intraday range of $4.65 to $5.23 represented nearly 12% of Friday's close — wide, but not unusual for a name whose average absolute daily move over the past 60 sessions is about 2.3%.
The move was company-specific rather than sector-driven. Large-cap healthcare and biotechnology benchmarks were mixed to slightly higher, and specialty pharmaceutical peers showed no uniform direction, so the session's gain cannot be attributed to a sector-wide bid. Technically, the stock remains well below its 20-day moving average, and Monday's fade from the highs suggests the $5.00–$5.25 band is acting as near-term resistance, with $4.65 now the reference support level.
The score runs from 0 to 100, where 0 means no meaningful news and a move that is normal for the stock, while 100 means transformative news and an extreme, rare price move. CorMedix earns 19 out of 100.
The verified news was modest in absolute terms: an insider purchase worth roughly $391,000 is meaningful as a sentiment signal but immaterial to the finances of a company with $355 million in cash. The price move was likewise unremarkable by the stock's own standards — about 1.4 times its typical daily change, with nine of the last 60 sessions posting moves of equal or greater size. A small catalyst and an ordinary-for-this-stock move combine into a low score.
The most immediate item is Heron Therapeutics' (HRTX) stockholder vote on the asset purchase agreement, with closing targeted for the first quarter of 2027. Integration planning, the drawdown of the $75 million term loan tranche from Pharmakon, and any update on Medicare Advantage contracting before year-end are the next checkpoints management has flagged.
On the regulatory side, the FDA is reviewing the supplemental application for REZZAYO in prophylaxis of invasive fungal disease under priority review, with a target action date in the first quarter of 2027 and promotional activity planned for the second half of that year if approved. Investors should also watch whether the company restores 2027 DefenCath guidance early next year, how dialysis customers respond to the quarterly add-on framework, and enrollment in the Phase III TPN study, which has lagged original timelines. Key risks include continued pricing pressure, customer concentration among a handful of dialysis providers, litigation exposure around one of the acquired Heron products, and dilution from the share consideration.
Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions are surfaced in the curated Trending AI Robots section. The bots differ by strategy, timeframe, performance metrics, and the symbols they trade, giving users a way to compare live approaches side by side rather than relying on static backtests. For readers tracking volatile small-cap names such as CorMedix, the page offers a practical starting point for evaluating automated strategies. Explore the current leaderboard to see which bots are performing best right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CRMD saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 30, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 40 instances where the indicator turned negative. In 36 of the 40 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRMD as a result. In 75 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
CRMD moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for CRMD moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for CRMD entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRMD advanced for three days, in 230 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CRMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is 19 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.900) is normal, around the industry mean (3.592). P/E Ratio (2.163) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (5.636) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (1.564) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. CRMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of medical devices for cardiovascular and kidney diseases
Industry Biotechnology